Bionano Genomics, Inc.
BNGOHealthcareNASDAQMedical Instruments & Supplies · Last scanned Sep 9, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Bionano Genomics, Inc. focuses on Medical Instruments & Supplies services and products. Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. Valued at $14.1M, BNGO is a micro-cap name in its sector. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants.
Market Cap
$14.1M
Beta
1.65
P/E (TTM)
—
P/E (Fwd)
-1.24
EPS (TTM)
$-3.00
EPS (Fwd)
$-0.97
ROE
-83.6%
ROA
-32.6%
Cash
$9.9M
Total Debt
$6.7M
Free CF
$2.3M
52W Change
-75.6%
Annual Financials
Cash vs Debt
Where BNGO stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, BNGO finished 7.63% above its 150-day moving average ($1.18) and 0.78% below its 200-day moving average ($1.28). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BNGO overbought or oversold?
At the September 3, 2026 close, BNGO's RSI(14) was 63.6, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Bionano Genomics, Inc. holds $9.9M in cash against $6.7M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Annual free cash flow of $2.3M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -83.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been relatively flat, moving from $27.8M (2022) to $28.5M (2025).
With a beta above 1.5, BNGO tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. No single metric tells the full story. Reviewing BNGO's risk profile alongside its fundamentals and technical indicators provides a more complete picture.